Genenta Announces Ongoing Clinical Trial Progress and

Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication...

Related Keywords

Milan ,Lombardia ,Italy ,Pierluigi Paracchi ,Tiziana Pollio ,Company Selects Refractory Advanced Genitourinary Malignancies ,Exchange Commission ,Renal Cell Cancer ,Glioblastoma Multiforme ,Overall Survival ,Refractory Advanced Genitourinary Malignancies ,Urogenital Cancer ,Chief Executive Officer ,Interferon Alpha ,Securities Litigation Reform Act ,Annual Report ,